Atai Beckley Inc. (NASDAQ:ATAI) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 20, 2026, Canaccord ...
AtaiBeckley Inc (NASDAQ:ATAI) is among the must-buy penny stocks to invest in now. The stock has gained more than 180% over ...
View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.
Stocktwits on MSN
ATAI stock soars on track for best day on Trump psychedelics push and Wall Street cheers
Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on ...
EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points ...
Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...
NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel ...
atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...
Loop Capital initiated coverage of the stock with a buy rating. atai has several therapies in late-stage trials but no marketed drugs yet. The company said it has enough cash to fund operations ...
Clinical stage biopharma company atai Life Sciences ATAI announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug delivery) ...
In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results